$19.730
+0.460 (+2.33%)At close
SPTX Comparative Benchmarking
In the context of the broader market, SPTX competes directly with industry leaders such as NBTX and MNKD. With a market capitalization of $1.03B, it holds a significant position in the sector. When comparing efficiency, SPTX's gross margin of N/A stands against NBTX's 100.00% and MNKD's 69.00%. Such benchmarking helps identify whether Seaport Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Seaport Therapeutics Inc Financial Performance
Seaport Therapeutics has shown a significant increase in total equity from $209.7 million in Q1 2026 to $422.6 million in Q2 2026, indicating a strong financial position despite ongoing losses. The current ratio has also improved to 18.00, suggesting good liquidity.
Financials
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.